BioCentury | Sep 20, 2019
Company News

Approval of Novo’s Rybelsus gives diabetes patients first oral option in GLP-1R class

...vs. 0.9% (p<0.001) at week 26. Rybelsus was developed using Eligen drug delivery technology from Emisphere Technologies Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...via maternal immunization Phase III final data 1Q19 Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) / Emisphere Technologies Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...in premenopausal women Submit sNDA; submit MAA 1H18; 2018 Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) / Emisphere Technologies Inc....
BioCentury | Jun 22, 2016
Company News

Management tracks

...of Finance Peter Pfreundschuh is resigning, effective June 27. Michael Garone, who was CFO at Emisphere Technologies Inc....
BioCentury | Nov 16, 2015
Company News

Emisphere, Novo Nordisk deal

...classes of Novo’s products, including those for diabetes and obesity, using Emisphere’s oral Eligen technology. Emisphere...
...granted Novo exclusive rights to three molecule classes and non-exclusive rights to a fourth class. Emisphere...
...exclusive molecule classes and up to $20 million in development milestones for the non-exclusive class. Emisphere...
BioCentury | Feb 23, 2015
Clinical News

Oral semaglutide: Phase II data

...1 trial to treat treatment-naïve Type II diabetics. The oral formulation uses Eligen technology from Emisphere Technologies Inc....
BioCentury | Sep 1, 2014
Financial News

Emisphere completes debt financing

...Date completed: 2014-08-20 Type: Debt financing Raised: $5 million Investor: MHR Fund Management LLC Note: Emisphere...
...Emisphere’s oral Eligen B12 product, which the company plans to commercialize as a medical food. Emisphere...
BioCentury | Dec 19, 2013
Cover Story

Oral nanoparticles

...tablet from Emisphere Technologies Inc. failed in a Phase II trial in type 2 diabetes. In 2011, Emisphere...
...salmon calcitonin biologic SMC021 after it failed several Phase III trials in osteoarthritis and osteoporosis. Emisphere...
...R.I. The David H. Koch Institute for Integrative Cancer Research at MIT , Cambridge, Mass. Emisphere Technologies Inc....
BioCentury | Aug 19, 2013
Clinical News

Oral semaglutide: Phase I data

...significantly reduced HbA1c vs. placebo in Type II diabetics. The product uses Eligen technology from Emisphere Technologies Inc....
BioCentury | May 6, 2013
Company News

Emisphere, Novo Nordisk deal

...and Novo Nordisk amended a 2008 deal granting Novo Nordisk an exclusive license to use Emisphere's...
...Novo Nordisk's glucagon-like peptide-1 (GLP-1) receptor agonists to treat Type II diabetes. Under the amendment, Emisphere...
...for reducing the rate of potential future royalty payments from products developed under the collaboration. Emisphere...
Items per page:
1 - 10 of 307
BioCentury | Sep 20, 2019
Company News

Approval of Novo’s Rybelsus gives diabetes patients first oral option in GLP-1R class

...vs. 0.9% (p<0.001) at week 26. Rybelsus was developed using Eligen drug delivery technology from Emisphere Technologies Inc....
BioCentury | Jan 5, 2019
Finance

Ready to launch

...via maternal immunization Phase III final data 1Q19 Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) / Emisphere Technologies Inc....
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

...in premenopausal women Submit sNDA; submit MAA 1H18; 2018 Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) / Emisphere Technologies Inc....
BioCentury | Jun 22, 2016
Company News

Management tracks

...of Finance Peter Pfreundschuh is resigning, effective June 27. Michael Garone, who was CFO at Emisphere Technologies Inc....
BioCentury | Nov 16, 2015
Company News

Emisphere, Novo Nordisk deal

...classes of Novo’s products, including those for diabetes and obesity, using Emisphere’s oral Eligen technology. Emisphere...
...granted Novo exclusive rights to three molecule classes and non-exclusive rights to a fourth class. Emisphere...
...exclusive molecule classes and up to $20 million in development milestones for the non-exclusive class. Emisphere...
BioCentury | Feb 23, 2015
Clinical News

Oral semaglutide: Phase II data

...1 trial to treat treatment-naïve Type II diabetics. The oral formulation uses Eligen technology from Emisphere Technologies Inc....
BioCentury | Sep 1, 2014
Financial News

Emisphere completes debt financing

...Date completed: 2014-08-20 Type: Debt financing Raised: $5 million Investor: MHR Fund Management LLC Note: Emisphere...
...Emisphere’s oral Eligen B12 product, which the company plans to commercialize as a medical food. Emisphere...
BioCentury | Dec 19, 2013
Cover Story

Oral nanoparticles

...tablet from Emisphere Technologies Inc. failed in a Phase II trial in type 2 diabetes. In 2011, Emisphere...
...salmon calcitonin biologic SMC021 after it failed several Phase III trials in osteoarthritis and osteoporosis. Emisphere...
...R.I. The David H. Koch Institute for Integrative Cancer Research at MIT , Cambridge, Mass. Emisphere Technologies Inc....
BioCentury | Aug 19, 2013
Clinical News

Oral semaglutide: Phase I data

...significantly reduced HbA1c vs. placebo in Type II diabetics. The product uses Eligen technology from Emisphere Technologies Inc....
BioCentury | May 6, 2013
Company News

Emisphere, Novo Nordisk deal

...and Novo Nordisk amended a 2008 deal granting Novo Nordisk an exclusive license to use Emisphere's...
...Novo Nordisk's glucagon-like peptide-1 (GLP-1) receptor agonists to treat Type II diabetes. Under the amendment, Emisphere...
...for reducing the rate of potential future royalty payments from products developed under the collaboration. Emisphere...
Items per page:
1 - 10 of 307